The following IPOs are expected to price this week:
Aviv REIT (AVIV), a REIT specializing in post-acute and long-term care skilled nursing facilities, plans to raise $251 million by offering 13.2 million shares at a price range of $18.00 to $20.00. At the midpoint of the proposed range, Aviv REIT would command a market value of $908 million. Aviv REIT, which was founded in 2005, booked $123 million in sales over the last 12 months. The Chicago, IL-based company plans to list on the NYSE under the symbol AVIV. Morgan Stanley, BofA Merrill Lynch and Goldman Sachs are the joint bookrunners on the deal.
Cancer Genetics (CGIX), which offers personalized genomic tests to improve the diagnosis and treatment of cancer, plans to raise $18 million by offering 1.7 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Cancer Genetics would command a market value of $56 million. Cancer Genetics, which was founded in 1999, booked $4 million in sales over the last 12 months. The Rutherford, NJ-based company plans to list on the NASDAQ under the symbol CGIX. Aegis Capital is the sole bookrunner on the deal.
Enanta Pharmaceuticals (ENTA), a biotech focused on developing small molecule drugs to use against hepatitis C, plans to raise $60 million by offering 4.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Enanta Pharmaceuticals would command a market value of $253 million. Enanta Pharmaceuticals, which was founded in 1996, booked $69 million in sales over the last 12 months. The Watertown, MA-based company plans to list on the NASDAQ under the symbol ENTA. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal.
Five Oaks Investment (FOIC), a REIT focused on investing in, financing and managing agency and non-agency RMBS, plans to raise $86 million by offering 5.7 million shares at a price of $15.00. At the proposed price, Five Oaks Investment would command a market value of $111 million. Five Oaks Investment, which was founded in 2012, booked $6 million in sales over the last 12 months. The New York, NY-based company plans to list on the NYSE under the symbol FOIC. Barclays, Credit Suisse, UBS Investment Bank and Keefe Bruyette Woods are the joint bookrunners on the deal.
HF2 Financial Management (HTWO), a blank check company formed to acquire a financial services company, plans to raise $153 million by offering 15.3 million shares at a price of $10.00. At the proposed price, HF2 Financial Management would command a market value of $405 million. HF2 Financial Management was founded in 2012. The Denver, CO-based company plans to list on the NASDAQ under the symbol HTWO. EarlyBird Capital is the lead bookrunner on the deal.
Marin Software (MRIN), which provides a cloud-based digital ad management platform, plans to raise $84 million by offering 7.0 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, Marin Software would command a market value of $399 million. Marin Software, which was founded in 2006, booked $60 million in sales over the last 12 months. The San Francisco, CA-based company plans to list on the NYSE under the symbol MRIN. Goldman Sachs and Deutsche Bank are the joint bookrunners on the deal.
Model N (MODN), which provides revenue management software to the life science and technology sectors, plans to raise $87 million by offering 6.5 million shares at a price range of $12.50 to $14.50. At the midpoint of the proposed range, Model N would command a market value of $331 million. Model N, which was founded in 1999, booked $89 million in sales over the last 12 months. The Redwood City, CA-based company plans to list on the NYSE under the symbol MODN. J.P. Morgan and Deutsche Bank are the joint bookrunners on the deal.
Tetraphase Pharmaceuticals (TTPH), which is developing antibiotics to treat serious abdominal and urinary tract infections, plans to raise $75 million by offering 6.8 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Tetraphase Pharmaceuticals would command a market value of $189 million. Tetraphase Pharmaceuticals, which was founded in 2006, booked $8 million in sales over the last 12 months. The Watertown, MA-based company plans to list on the NASDAQ under the symbol TTPH. Barclays and BMO Capital Markets are the joint bookrunners on the deal.
West Corporation (WSTC), which is a leading conferencing and call center provider LBO'd by TH Lee and Quadrangle, plans to raise $500 million by offering 21.3 million shares at a price range of $22.00 to $25.00. At the midpoint of the proposed range, West Corporation would command a market value of $2.0 billion. West Corporation, which was founded in 1986, booked $2.6 billion in sales over the last 12 months. The Omaha, NE-based company plans to list on the NASDAQ under the symbol WSTC. Goldman Sachs, Morgan Stanley, BofA Merrill Lynch and Barclays are the joint bookrunners on the deal.
Renaissance Capital will have Pre-IPO Research available on each of these upcoming IPOs prior to its pricing.
Last week, there was one IPO pricing. Silver Spring Networks (SSNI), which provides smart grid products and services to utilities, ended up 25% from its IPO price.
